Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes
Study Details
Study Description
Brief Summary
The aim of the study is to evaluate the efficacy, safety and feasibility of outpatient-utilization of low-dose dasiglucagon administered via a multi-dose reusable pen injector in preventing and treating mild hypoglycemia in insulin pump-treated people with type 1 diabetes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
A randomized, open-label, two-arm, two-week crossover study will be conducted to assess the study objectives. The study will enroll 24 participants with insulin pump-treated type 1 diabetes. Upon study enrollment, participants will complete two consecutive 2-week periods - a 'usual care' period and 'dasiglucagon' period. During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension. During the 'dasiglucagon' period, participants will use pen-administered low-dose dasiglucagon to treat or prevent episodes of hypoglycemia.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Usual care During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension. |
|
| Experimental: Dasiglucagon During the 'dasiglucagon' period, participants will use pen-administered low-dose (80 µg) dasiglucagon to treat or prevent episodes of hypoglycemia. |
Drug: Dasiglucagon
Abdominal s.c. administration using a multi-dose reusable pen injector
|
Outcome Measures
Primary Outcome Measures
- Difference in percentage of time in range between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Sensor glucose level ≥ 3.9 mmol/l and ≤ 10.0 mmol/l
Secondary Outcome Measures
- Difference in percentage of time in hypoglycemia between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Sensor glucose level < 3.9 mmol/l
- Difference in percentage of time in hyperglycemia between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Sensor glucose level > 10 mmol/l
- Difference in coefficient of variation (%) between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
- Difference between successful cases (%) of hypoglycemia treatment between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Initial sensor glucose level ≥ 2.2 mmol/l and ≤ 3.9 mmol/l AND sensor glucose level > 3.9 mmol/l 30 minutes post-treatment
- Difference in successful cases (%) of hypoglycemia treatment without subsequent hyperglycemia [sensor glucose level > 10 mmol/l during the first two hours post-treatment] between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Initial sensor glucose level ≥ 2.2 mmol/l and ≤ 3.9 mmol/l AND sensor glucose level > 3.9 mmol/l 30 minutes post-treatment AND sensor glucose level ≤ 10 mmol/l during the first two hours post-treatment
- Difference in successful cases (%) of hypoglycemia prevention between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Initial sensor glucose level > 3.9 mmol/l AND sensor glucose level < 3.9 for ≤ 15 consecutive minutes during the first two hours post-treatment
- Difference in time from hypoglycemia treatment to euglycemia between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Minutes from initial sensor glucose level ≥ 2.2 mmol/l and ≤ 3.9 mmol/l to sensor glucose level ≥ 3.9 mmol/l
- Incidence rate of supplement carbohydrate administration during the first hour following dasiglucagon administration [2-week 'dasiglucagon' period]
- Difference between the average daily carbohydrate intake between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Registered on the insulin pump
- Difference between the average total daily insulin dose between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
- Difference in the number and intensity of episodes with nausea, headache, stomach-ache, palpitations and injection site pain between the two study periods [2-week 'usual care' period and 2-week 'dasiglucagon' period]
Intensity: mild/moderate/severe
- Percentage of participants scoring a favorable outcome on the patient-reported outcome questionnaire [At the end-of-study visit (estimated week 6)]
Scoring likely OR very likely on a four-point Likert scale
- Percentage of participants with treatment-induced or treatment-boosted anti-dasiglucagon antibodies [Measured 4 weeks after the 'dasiglucagon' period]
Other Outcome Measures
- Number of device failures/malfunctions [2-week 'dasiglucagon' period]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years
-
T1D ≥ 2 years
-
Use of insulin pump therapy (without sensor-augmented insulin suspension/adjustment functionality) ≥ 6 months
-
Use of CGM (real-time or intermittently scanned) ≥ 3 months and ≥ 70% during the previous 14 days
-
HbA1c ≤ 70 mmol/l (8.5%)
-
Performs aerobic exercise on a regular basis (≥ 2 times per week; self-reported) and desires to exercise per American Diabetes Association guidelines (150 minutes per week) during the study.
-
Use of carbohydrate counting and bolus calculator (self-reported)
-
Sensor glucose level < 3.9 mmol/l on ≥ 4/14 previous days assessed by CGM data
Exclusion Criteria:
-
Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period and within 30 days prior to study start
-
Known or suspected allergies to glucagon or related products
-
History of hypersensitivity or allergic reaction to dasiglucagon or any of the excipients
-
Patients with pheochromocytoma or insulinoma
-
Hypoglycemia unawareness
-
Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
-
Inability to understand the individual information and to give informed consent
-
Current participation in another clinical trial that, in the judgment of the investigator, will compromise the results of the study or the safety of the subject
-
Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Steno Diabetes Center Copenhagen | Gentofte | Denmark | 2820 |
Sponsors and Collaborators
- Steno Diabetes Center Copenhagen
Investigators
- Principal Investigator: Christian Laugesen, MD, Steno Diabetes Center Copenhagen
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 77119
- H-21000002
- 2020-005745-16